Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

BI 765423

Source date not recordedAnalyse record ↗

Anti-IL-11 antibody in an active Phase 2a study for idiopathic pulmonary fibrosis.

Modality
intravenous anti-interleukin-11 monoclonal antibody
Availability (US)
Phase 2a idiopathic-pulmonary-fibrosis study Active, not recruiting
Biomarkers
forced vital capacity; adverse events; pharmacokinetics; pharmacodynamic markers
Hallmark targeted
extracellular-matrix remodeling, fibrosis, altered intercellular communication
Kind
investigational biologic
Clinical trials
NCT07036523 — Phase 2, Active, not recruiting on September 25, 2026 update